Mycosis fungoides (MF) is the most common cutaneous T-cell lymphoma (CTCL). Causative genetic alterations in MF are unknown. The low recurrence of pathogenic small-scale mutations (ie, nucleotide substitutions, indels) in the disease, calls for the study of additional aspects of MF genetics. Here, we investigated structural genomic alterations in tumor-stage MF by integrating whole-genome sequencing and RNA-sequencing. Multiple genes with roles in cell physiology (n = 113) and metabolism (n = 92) were found to be impacted by genomic rearrangements, including 47 genes currently implicated in cancer. Fusion transcripts involving genes of interest such as DOT1L, KDM6A, LIFR, TP53, and TP63 were also observed. Additionally, we identified recurrent deletions of genes involved in cell cycle control, chromatin regulation, the JAK-STAT pathway, and the PI-3-K pathway. Remarkably, many of these deletions result from genomic rearrangements. Deletion of tumor suppressors HNRNPK and SOCS1 were the most frequent genetic alterations in MF after deletion of CDKN2A. Notably, SOCS1 deletion could be detected in early-stage MF. In agreement with the observed genomic alterations, transcriptome analysis revealed upregulation of the cell cycle, JAK-STAT, PI-3-K and developmental pathways. Our results position inactivation of HNRNPK and SOCS1 as potential driver events in MF development.
To date, no study has provided insight into the landscape of genomic rearrangements underlying MF. Consequently, we performed an integrated whole-genome sequencing (WGS)/RNA-sequencing (RNA-seq) analysis of tumor-stage MF to investigate structural aberrations at base-level resolution.
Our results reveal numerous rearrangements associated with CNAs, and affecting genes involved in signal transduction and transcriptional regulation. Moreover, we identify two recurrently deleted tumor suppressors, HNRNPK and SOCS1, that are novel to MF genetics. These findings broaden our understanding of MF and provide new potential targets for treatment.
| MATERIALS AND METHODS

| Patient selection
Frozen skin biopsies from nine patients with tumor-stage MF (IIB-IVA2, Supporting Information Table 1 ) were selected for this study. Diagnosis was based on the criteria of the WHO-EORTC classification for primary cutaneous lymphomas 1 and confirmed by an expert panel of dermatologist and pathologists. We subjected eight tumor biopsies to WGS and RNA-seq, and one biopsy to WGS only. Eighteen additional frozen tumor biopsies (IIB-IVA2, Supporting Information Table 1) 
| DNA and RNA isolation
Genomic DNA was isolated using Genomic-tip 20/G kit (Qiagen) following the manufacturer's protocol. DNA purity (A260/280 and A260/230 ratios) was evaluated using a Nanodrop 1000 system (Nanodrop Technologies, Wilmington, CA). DNA integrity was verified by gel electrophoresis (0.7% agarose, ethidium bromide). Total RNA was isolated using RNeasy mini kit (Qiagen). RNA integrity was verified with an Agilent 2100 Bioanalyzer.
| Sequencing
DNA and RNA were sequenced by the Beijing Genomics Institute (BGI). For whole-genome sequencing, DNA libraries were prepared using TruSeq Nano DNA HT sample prep kit (Illumina), which involves DNA fragmentation by Covaris sonication, end-repair, A-tailing, adapter ligation, and fragment enrichment. Purified DNA fragments were subjected to paired-end sequencing (2 × 150 bp) on the Illumina HiSeq X-Ten platform. For RNA sequencing, total RNA was depleted from rRNA using Ribo-Zero Magnetic kit (Epicentre Biotechnologies, Madison, WI), fragmented, and followed by first-strand cDNA synthesis, second-strand cDNA synthesis (with dUTP instead of dTTP), end repair, A-tailing, adapter ligation, uracil-N-glycosylase treatment, and cDNA library enrichment. Purified cDNA libraries were subjected to paired-end sequencing (2 × 100 bp) on the Illumina HiSeq 4000 platform. All NGS data have been deposited in the European GenomePhenome Archive (EGA) under study number EGAS00001002860.
| Sequence data processing
For whole-genome sequencing, raw reads were processed using FastQC (v0.11.2), SeqTK (v1.0-r63), Cutadapt, and Sickle (v1.33).
Clean reads were aligned to the human reference genome Hg19 using BWA-mem (v0.7.10) (Supporting Information 
| Discovery of pathogenic SNVs
SNVs were detected using GATK (v3.5). SNVs present in the dbSNP database were filtered out. We searched for pathogenic SNVs in 1461 genes involved in signaling pathways and cellular processes previously reported as affected in CTCL. [7] [8] [9] [16] [17] [18] [19] [20] [21] [22] Reported copy numbers of HNRNPK and SOCS1 in samples from the validation cohort are the average of three independent measurements using different reference genes.
3 | RESULTS
| Landscape of genomic rearrangements
The number of rearrangements ranged from 13 to 62 per patient A total of 270 genes were found to be rearranged (Supporting Information Table 6 ), 47 of which are currently implicated in cancer (Supporting Information Table 7 ). This group includes genes previously associated with MF or Sézary Syndrome (SS) (ie, CDKN2A, CDKN2B, DLEU2, KDM6A, TP53, TP63, and VAV1) 5, 19 and genes implicated in other hematological malignancies (eg, ARHGAP26, CBFA2T3, CHD2, DOT1L, LCK, LPP, PBX1, PTPN11, MLLT3, TAF15, SPECC1, ZMYM2) ( Figure 1 ). [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] Functional annotation of rearranged genes reveals a diverse set of biological processes ( Figure 2E ; Supporting Information Table 8 Table 8 ).
In support of the postulated deleterious effects of genomic rearrangements on normal cellular functions, at least 100 rearranged genes (127/270 genes could not be assigned to a protein class by Panther) encode proteins with relevant roles in signal transduction (eg, ligands, receptors, enzyme modulators) and transcriptional regulation (eg, transcription factors, chromatin regulators) ( Figure 2F ; Supporting Information Table 9 ). Nonetheless, rearranged genes do not group into a single or a few signaling pathways, but take part in numerous different pathways/processes. 
| Aneuploidies and CNAs
Large-scale numerical abnormalities (>3 Mb) included trisomy 4 (one of nine patients), 7 (two of nine) and 18 (two of nine), as well as deletions within 9q (four of nine patients), 10q (two of nine) and 16q
(three of nine), and gains within 3q (three of nine patients), 5p (three of nine), 7q (two of nine), 8q (two of nine) and 17q (four of nine) ( Figures 3 and 4) .
We identified 18 focal (≤3 Mb) minimal common regions (MCRs)
shared by CNAs, with 15/18 MCRs containing cancer genes (Figures 3 and 4 ; Supporting Information Table 10 ). These focal MCRs affect genes primarily involved in cell cycle control, chromatin regulation, the JAK-STAT pathway, and the PI-3-K pathway.
The most frequent focal MCR was 9p21.3 deletion, found in seven of nine patients. This region encloses exon 2 and 3 of CDKN2A.
We found deletions at 16p13. In contrast, focal MCRs within gain areas were rare (n = 3), with gain at 8q24.21 (involving MYC) found in two of nine patients, being the only event containing a cancer gene.
| Pathogenic SNVs
Prior studies showed that recurrent pathogenic SNVs in MF are rare. 7-9,19 Nevertheless, we looked for pathogenic SNVs in exonic sequences of genes involved in the JAK-STAT pathway, the MAPK pathway, the NF-κB pathway, the PI-3-K pathway, the T-cell receptor (TCR) pathway, cell cycle control, chromatin organization, and genes that are presumed drivers 19 in CTCL (Supporting Information 
| Differentially expressed genes and fusion transcripts
We identified differentially expressed (DE) genes by comparing expression in our MF cohort with expression in normal CD4+ T cells.
Since the cell of origin of MF remains unidentified, transcriptome analysis was performed using a control group formed by several CD4+ T- We detected 24 patient-specific fusion transcripts (Table 1) ATXN1-TP63, 49 all these chimeric transcripts are reported for the first time.
| Deregulated signaling pathways
To look for evidence of deregulated pathways in MF, we performed GSEA using annotated gene sets from MSigDB to look for expression signatures. The analysis revealed up-regulation of IL6-JAK-STAT3 signaling (NES = 1.75, FDR q-value = 2.62 × 10 Table 15 ). Information Table 15 for a complete list of GSEA signatures). NES, normalized enrichment score; FDR q-value, false discovery rate q-value. F and G, Pathway analysis by DAVID reveals up-regulation of the PI-3-K/Akt pathway, the cell cycle and cancer signatures, and down-regulation of ribosome, spliceosome and mRNA surveillance (see Supporting Information Table 16 ) and spliceosome (P = 8.7 × 10 −9 ) activity, and mRNA surveillance (P = 4.1 × 10 −4 ) ( Figure 5G ; Supporting Information Table 16 ).
3.6 | SOCS1 and HNRNPK are recurrently deleted and SOCS1 in 9 of 27 (33%) patients.
| Deletion of SOCS1 can be found at early stage
We seized upon the fact that SOCS1 deletions mostly result from translocations in our sequenced cohort to investigate their occurrence at early stage. We used a combination of break-apart and fusion FISH to search for SOCS1-deleting translocations in available plaque-stage tissue from two sequenced patients (MF3 and MF4) with confirmed SOCS1-deleting translocations in tumor-stage tissue ( Figure 6 ). Plaque biopsies from patients MF3 and MF4 were procured, respectively, 3 years and 8 months prior to tumor development. We found that patient MF4 bears the translocation at plaque-stage too ( Figure 7E ), suggesting that SOCS1 deletion is an early event in this individual.
| DISCUSSION
This study represents the first integrated analysis (DNA/RNA) of genomic rearrangements in MF. The analysis reveals that MF displays a complex and heterogeneous landscape of inter-and intrachromosomal rearrangements. We observed, among others, translocations leading to deletion of ARID1A, CDKN2A/B, PTPRC, SOCS1, and STK11.
This suggests that rearrangements mediate the deletion of tumor suppressors involved in pathways that are commonly deregulated in MF patients. We detected 270 rearranged genes, of which at least 100 play diverse roles in signal transduction and transcriptional regulation, and 47 are currently implicated in neoplasms. Our analysis identified 24 fusion transcripts, including 6 containing bona fide cancer Additionally, up-regulation of mitotic checkpoint kinase TTK might contribute to genomic instability in MF, since its expression has been shown to prevent aneuploidy-induced cell death. 62 On the other hand, up-regulation of developmental genes GLI3, JAG1, and NOTCH3 might contribute to boost cell proliferation. Notably, NOTCH3 overactivation has been shown to induce an autosustaining JAG1 expression loop in T-cell acute lymphoblastic leukemia (T-ALL), which in turn, enhances expression of Notch target genes responsible for the progression of the disease. 63 Moreover, transcriptome analysis also shows that processes related to transcription (ie, spliceosome activity, mRNA surveillance) are flawed in MF, which might be linked to the considerable number of transcription-related genes affected by genomic rearrangements.
Taken together, the structural and expression analyses show that the cell cycle, the JAK-STAT pathway, the PI-3-K pathway, and developmental pathways are deregulated in MF.
We report for the first time recurrent deletion of HNRNPK and SOCS1 not only in MF, but any CTCL. Furthermore, we found evidence that SOCS1 deletion is an early event in one of two patients with available plaque-stage material by FISH. Importantly, while the incidence of deletion of both genes in the extension cohort was lower compared to the sequenced cohort, this difference was not hnRNP-K is a nuclear ribonucleoprotein implicated in leukemogenesis of acute myeloid leukemia (AML). 59 Interestingly, studies have
shown that haploinsufficiency of HNRNPK not only down-regulates p21, but also up-regulates STAT3 signaling and give rise to B-and Tcell lymphomas in a mouse model. 59 On the other hand, SOCS1, which is silenced in several cancers including multiple myeloma (MM), 64 inhibits JAK-STAT signaling by suppressing the tyrosine kinase activity of JAK proteins. 65 A noteworthy fact is that miR-155, which is often up-regulated in MF, 6 has been found to target SOCS1 in breast cancer and laryngeal carcinoma, leading to constitutive STAT3 activation in both cancers. 66, 67 We observed that two of three patients without SOCS1
deletions express much higher levels (sevenfold average) of miR-155 precursor MIR155HG than patients with SOCS1 deletions (Supporting Information Figure 5 ), which suggests that miR-155 levels rise to inhibit SOCS1 in patients with functional copies of the gene. Moreover, SOCS1 might be suppressed in MF in one additional way.
MECOM, which is consistently up-regulated in our sequenced cohort, has been found to inhibit the expression of several regulators of the JAK-STAT pathway in AML, particularly SOCS1. 68 This evidence suggests that deregulation of STAT3 signaling via inactivation of HNRNPK and SOCS1 might be important in the pathogenesis of MF. Future studies with cells and animal models will be essential to functionally confirm the association between these tumor suppressors, their regulators, and STAT3 signaling in MF. In this scenario, targeting miR-155 and/or MECOM to treat patients with functional SOCS1 alleles consti-
